Lancashire and South Cumbria
Formulary
Formulary
7 Obstetrics, Gynaecology, and urinary-tract disorders
07-02-01 Topical HRT
Transdermal oestrogens are absorbed and should be used in the smallest effective amount and if required long term should be combined with an oral progestogen in women with an intact uterus. For low-dose vaginal oestrogen, a progesterone is not needed for endometrial protection, as systemic absorption of vaginal oestrogen is minimal.
| Estradiol vaginal 10 microgram tablet |
|
Formulary
|
Vaginal tablets 10microgram |
 MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping |
|
| Prasterone |
|
Formulary
|
Vulvovaginal or vaginal atrophy in postmenopausal women having moderate to severe symptoms. |
|
LSCMMG: Prasterone |
|
Links
- FSRH Clinical Guideline: Contraceptive Choices for Young People
- FSRH: Standards & Guidance
- FSRH: UK Medical Eligibility Criteria for Contraceptive Use (UKMEC)
- LSCMMG: Prasterone
LSCMMG: Primary Care Management of Erectile Dysfunction- LSCMMG: Primary Care Management of Overactive Bladder in Female Adults
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed?
- NICE CG30: Long-acting reversible contraception
- NICE CG97: Lower urinary tract symptoms in men: management
- NICE NG123: Urinary incontinence and pelvic organ prolapse in women: management
- NICE NG133: Hypertension in pregnancy: diagnosis and management
- NICE NG194: Postnatal care
- NICE NG210: Pelvic floor dysfunction: prevention and non-surgical management
- NICE NG3: Diabetes in pregnancy: management from preconception to the postnatal period
- NICE NG88: Heavy menstrual bleeding: assessment and management